Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative Journal Article
| Authors: | Bogaerts, J.; Sydes, M. R.; Keat, N.; McConnell, A.; Benson, A.; Ho, A.; Roth, A.; Fortpied, C.; Eng, C.; Peckitt, C.; Coens, C.; Pettaway, C.; Arnold, D.; Hall, E.; Marshall, E.; Sclafani, F.; Hatcher, H.; Earl, H.; Ray Coquard, I.; Paul, J.; Blay, J. Y.; Whelan, J.; Panageas, K.; Wheatley, K.; Harrington, K.; Licitra, L.; Billingham, L.; Hensley, M.; McCabe, M.; Patel, P. M.; Carvajal, R.; Wilson, R.; Glynne-Jones, R.; McWilliams, R.; Leyvraz, S.; Rao, S.; Nicholson, S.; Filiaci, V.; Negrouk, A.; Lacombe, D.; Dupont, E.; Pauporté, I.; Welch, J. J.; Law, K.; Trimble, T.; Seymour, M. |
| Article Title: | Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative |
| Abstract: | Background The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research. Settings The International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the development of international clinical trials for patients with rare cancers. It is focused on interventional - usually randomised - clinical trials with the clear goal of improving outcomes for patients. The key challenges are organisational and methodological. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was held in Amsterdam in September 2013. Other as-yet unrealised methods were also discussed. Results The IRCI trials are each presented to exemplify possible approaches to designing credible trials in rare cancers. Researchers may consider these for use in future trials and understand the choices made for each design. Interpretation Trials can be designed using a wide array of possibilities. There is no 'one size fits all' solution. In order to make progress in the rare diseases, decisions to change practice will have to be based on less direct evidence from clinical trials than in more common diseases. |
| Keywords: | cancer chemotherapy; cancer recurrence; squamous cell carcinoma; cisplatin; doxorubicin; fluorouracil; gemcitabine; paclitaxel; methodology; antineoplastic agent; neoplasm; carboplatin; metastasis; ifosfamide; docetaxel; ewing sarcoma; androgen receptor; penis carcinoma; salivary gland cancer; uvea melanoma; small intestine carcinoma; androgen deprivation therapy; uterus sarcoma; clinical trials; chemoradiotherapy; rare disease; randomized controlled trial (topic); study design; phase 2 clinical trial (topic); phase 3 clinical trial (topic); anus carcinoma; multicenter study (topic); bayesian; trametinib; cabozantinib; human; priority journal; article; uprosertib; frequentist; multi-arm; randomised controlled trials; rare cancers; high grade undifferentiated uterine sarcoma; penis squamous cell carcinoma; small bowel adenocarcinoma |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | 3 |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-02-01 |
| Start Page: | 271 |
| End Page: | 281 |
| Language: | English |
| DOI: | 10.1016/j.ejca.2014.10.027 |
| PROVIDER: | scopus |
| PUBMED: | 25542058 |
| PMCID: | PMC4639696 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work